NCT06295770View on ClinicalTrials.gov

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

PHASE2RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Fibrillary Glomerulonephritis

Interventions

DRUG

Obinutuzumab

Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.

Trial Locations (1)

55905

RECRUITING

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER

NCT06295770 - Obinutuzumab in Treatment of Fibrillary Glomerulonephritis | Biotech Hunter | Biotech Hunter